🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Liver Cancer, Adult

Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC NCT06876753n/a2 sites📍 Nanjing📍 Nanjing Zhongda Hospital Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation NCT06718153NA1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna · Tests: Immunohistochemistry and in situ hybridisation analysis FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma NCT07012798Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Durvalumab, Bevacizumab, HAIC of FOLFOX Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) NCT06561399n/a4 sites📍 Fuzhou📍 Fuzhou📍 Fuzhou Fujian Provincial Hospital · Tests: TACE, Lenvatinib combination with Sintilimab sequential radiotherapy Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma NCT07832006Phase 21 site📍 Beijing Shunda Du · Tests: Irreversible Electroporation, Lenvatinib, Sintilimab The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors NCT07159048NA1 site📍 Shanghai Fudan University · Tests: Multimodal Tumor Thermal Therapy System, Radiofrequency Ablation System or Microwave Ablation System TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC NCT07658833n/a1 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: TACE (transarterial chemoembolization) combined with targeted/immunotherapy Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC NCT06609876NA1 site📍 Beijing Sun Yat-sen University · Tests: Thermal ablation, Donafenib Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC NCT07500220Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma NCT05047510NA2 sites📍 Zhuhai📍 Luzhou Chinese Academy of Sciences · Tests: Anti-GPC3-IRDye800CW A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762Phase 162 sites📍 Birmingham📍 Birmingham📍 Birmingham Seagen, a wholly owned subsidiary of Pfizer · Tests: PF-08046054, pembrolizumab Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer NCT07174570Phase 24 sites📍 Atlanta📍 Atlanta📍 Atlanta Emory University · Tests: Celecoxib, Durvalumab, Tremelimumab, Biospecimen Collection, Computed Tomography Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH) NCT05870969n/a1 site📍 Shanghai Ruijin Hospital · Tests: Liver cancer surveillance every 3 months, Liver cancer surveillance every 6 months, Liver cancer surveillance annually 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors NCT07760012NA1 site📍 Beijing Peking University Third Hospital · Tests: 68Ga-SorB PET/CT Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05608200Phase 31 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment NCT07238881Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Dalpiciclib Isetionate Tablets, Dalpiciclib Isetionate Tablets, Camrelizumab (anti-PD-1 inhibitor) Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant NCT06725121Phase 1, Phase 22 sites📍 London📍 Toronto University Health Network, Toronto · Tests: Atezolizumab & Bevacizumab, Yttrium-90 (Y-90), Stereotactic body radiotherapy (SBRT) Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma NCT07413354Phase 21 site📍 Wuhan Tongji Hospital · Tests: Tislelizumab plus Huaier granule Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma NCT06475118NA1 site📍 Reims CHU de Reims · Tests: Dynamometry measurement, myokine dosing, sarcopenia calculation A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis NCT07291141n/a1 site📍 Linköping Mattias Ekstedt SBRT Versus Surgical Resection for Small HCC NCT07381660Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Stereotactic body radiotherapy (SBRT), Resection LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers NCT04665388n/a1 site📍 Toronto University Health Network, Toronto Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors NCT07485114n/a1 site📍 Tel Aviv Daniel Keizman · Tests: Serum Gal-3 level, blood count and chemistry included liver function A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions NCT06864195n/a1 site📍 London Imperial College London PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer NCT07884877Phase 21 site📍 Seoul Samsung Medical Center · Tests: PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy EGCG for Hepatocellular Carcinoma Chemoprevention NCT06015022Phase 21 site📍 Dallas University of Texas Southwestern Medical Center · Tests: Epigallocatechin gallate (EGCG), Placebo GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma NCT07795437NA1 site📍 Beijing Peking University First Hospital · Tests: 18F-X12 PET/CT Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment NCT07147101n/a1 site📍 Shanghai Fudan University · Tests: Sintilimab, Bevacizumab Biosimilar, Camrelizumab, Rivoceranib, Nivolumab Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy NCT07436845n/a1 site📍 Guangzhou Nanfang Hospital, Southern Medical University
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy